ArrowMark Colorado Holdings’s Seres Therapeutics MCRB Stock Holding History

ArrowMark Colorado Holdings’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-500	Closed	-$415K	–	292
2015 Q2	$415K	Buy	+500	New	+$436K	0.01%	278

Other funds holding MCRB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FV2GP

Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ArrowMark Colorado Holdings's MCRB Position: Q3 2015 in Review

ArrowMark Colorado Holdings sold out of Seres Therapeutics (MCRB) in Q3 2015, closing a stake of 500 shares — an estimated $415K sold.

ArrowMark Colorado Holdings first reported a position in MCRB in Q2 2015 and held it in 1 quarter. The position peaked at $415K in Q2 2015. 60 funds tracked by Wall St. Rank hold MCRB as of Q3 2015.

ArrowMark Colorado Holdings reported no remaining Seres Therapeutics position as of Q3 2015 after selling out during the quarter.
ArrowMark Colorado Holdings sold 500 Seres Therapeutics shares in Q3 2015, an estimated $415K.
ArrowMark Colorado Holdings first reported a position in Seres Therapeutics in Q2 2015 and held it in 1 quarter.
ArrowMark Colorado Holdings's Seres Therapeutics position peaked at $415K in Q2 2015.
60 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2015.

Based on ArrowMark Colorado Holdings's 13F filing for Q3 2015, filed 16 Nov 2015.